No efficacy or safety outcomes have been reported yet. The development moves into humans with MHRA approval for a first‑in‑human clinical investigation of OsStic, an injectable synthetic bone void filler, in tibial plateau fractures.
Biomimetic Innovations, an affiliate of PBC Biomed, will sponsor a single‑site study at Leeds Teaching Hospitals to assess device safety and early performance in periarticular fractures characterized by subchondral bone loss. Primary objectives center on adverse events and device‑related complications; secondary measures span maintenance of reduction, radiographic healing and remodeling, functional recovery, pain, quality of life, and exploratory gait analysis via plantar pressure mapping. Recruitment is expected to begin within weeks with completion targeted for 2028, positioning the trial as the foundational evidence set ahead of larger comparative studies.
Strategically, choosing tibial plateau fractures as the proving ground is a calculated bet. This indication routinely exposes the trade‑off between mechanical stability and biological integration that undermines both grafts and many conventional synthetics. OsStic is being positioned to harden rapidly, conform to irregular metaphyseal defects, and provide immediate subchondral support while permitting subsequent bone ingrowth. A controlled first‑site design at a high‑volume trauma center signals a risk‑managed approach to early use in an acute surgical workflow where intraoperative handling, containment, and avoidance of extravasation are critical. The inclusion of functional and gait metrics suggests the sponsor aims to connect radiographic endpoints with patient‑relevant recovery, a throughline increasingly important to NHS procurement and guideline bodies.
For sites, the operational lift will be in perioperative identification and consent within trauma pathways, standardized intraoperative application, and consistent imaging follow‑up over multiple years. The gait lab component adds coordination across surgical, rehabilitation, and biomechanics teams—manageable at a tertiary center but a preview of what broader adoption would demand. CROs and device monitors should expect intensive early procedural oversight and training along with long‑tail follow‑up discipline through 2028. For sponsors and competitors in the bone void filler market, the bar is shifting from basic radiographic fill to demonstrable maintenance of reduction and functional recovery in weight‑bearing periarticular settings where brittleness and resorption kinetics have historically driven failures. Regulators will look for clean early safety, especially around cement leakage, infection, and loss of reduction, before entertaining multicenter expansions.
The commercial and regulatory pathway remains open but not guaranteed. UK first‑in‑human data can underpin a UKCA submission and inform subsequent randomized comparative trials against standard calcium phosphate/calc‑sulfate cements or graft substitutes. Any claim of immediate mechanical support with remodeling will likely require head‑to‑head evidence, durability beyond 12 months, and cost‑utility signals to satisfy NICE and hospital value analysis committees. PBC Biomed’s history of bringing cements to market and transacting with strategics could accelerate partnering if the early handling and safety profile holds up, but single‑site generalizability, trauma enrollment variability, and the multi‑year timeline introduce execution risk.
What to watch next: intraoperative handling time and containment, early complication signals, maintenance of joint surface elevation at 3–12 months, and alignment between radiographic remodeling and gait/PRO improvements. The pivotal question is whether OsStic can convert a clean FIH safety readout into a multicenter, comparative program that proves clinical and economic advantage in periarticular trauma—without adding complexity to already strained trauma workflows.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
